Sanofi announced a definitive agreement to acquire Blueprint Medicines Corporation, a U.S.-based biopharmaceutical company focused on systemic mastocytosis (SM) and other KIT-driven diseases. This...
Sanofi announced the successful completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, a privately held, clinical-stage biopharmaceutical...
Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and...
Vir Biotechnology, Inc, announced that it has entered into an exclusive worldwide license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and...
Medidata, a Dassault Systèmes company and a leading provider of clinical trial solutions for the life sciences industry, and Sanofi Vaccines are leveraging Medidata eCOA to We...
